Project Grant R01AI184095
Award Date
8/2/24
Completion Date
6/30/29
Dollars Obligated
$1.6M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,283 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, effective August 16, 2024 through July 31, 2029, will support research to investigate the effects of targeting immune activation and intestinal barrier on comorbidities in people living with HIV. The research aims to advance...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $711,993 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Medical Center Corporation (BMC) on June 11, 2025. The grant supports research to understand the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 pathogenesis, immunity, and persistence in people living with HIV. Specifically, the project will assess how MTB disease impacts the HIV-1 immune response,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $681,278 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant, which runs from July 2024 to May 2026, will fund research to characterize the HIV latent reservoir and model the contributions of antigen-driven and homeostatic proliferation to its persistence in people living with HIV on antiretroviral therapy. The goal is to help design future HIV...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $490,788 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The grant, titled "Quantifying Genomic and Pharmacometabolomic Differences in Antiretroviral Exposure in MACS/WIHS Combined Cohort Study", aims to identify genetic and metabolic factors that influence the plasma concentrations and associated...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $765,274 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Boston Medical Center Corporation to investigate the role of defective HIV proviruses in perpetuating chronic inflammation among HIV-infected individuals. The research aims to determine if persistent expression of aberrant viral RNAs from defective proviruses promotes innate immune activation, examine differences in intact proviral...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...
This $760,038 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research by George Mason University to study the anti-HIV properties of the PSGL-1 protein, a newly identified HIV restriction factor. The research aims to determine the structure-function relationship of the PSGL-1 DR domain and its impact on anti-HIV activity through a combination of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $243,713 to the University of Massachusetts Medical School (UMass Medical) to conduct research on how HIV-infected macrophages evade killing by natural killer (NK) cells. The study aims to determine the mechanisms by which infected macrophages resist antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells,...